Publicaciones (27) Publicaciones de Antonio Martin Bastida

2024

  1. Brain 18F-FDG PET findings and sequential vestibular testing in SCA27B: a case report

    Journal of Neurology

  2. Magnetic Resonance-Guided Focused Ultrasound (MRgFUS)-Thalamotomy for Essential Tremor: Lesion Location and Clinical Outcomes

    Movement Disorders

2023

  1. Trastornos del movimiento

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 76, pp. 4481-4490

2022

  1. Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with 11C-BU99008 PET

    Brain Communications, Vol. 4, Núm. 5

  2. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease

    Nature Reviews Neurology, Vol. 18, Núm. 4, pp. 203-220

  3. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis

    Movement Disorders, Vol. 37, Núm. 5, pp. 1028-1039

2021

  1. Dissociable effects of age and Parkinson's disease on instruction-based learning

    Brain Communications, Vol. 3, Núm. 3

  2. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

    Neurology, Vol. 97, Núm. 14, pp. E1367-E1381

  3. Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease

    Frontiers in Neurology, Vol. 12

  4. Iron and inflammation: in vivo and post-mortem studies in Parkinson’s disease

    Journal of Neural Transmission, Vol. 128, Núm. 1, pp. 15-25

  5. Is chelation therapy a potential treatment for parkinson’s disease?

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  6. Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients

    Parkinsonism and Related Disorders, Vol. 87, pp. 61-69

  7. Parkinson’s disease laterality: a 11C-PE2I PET imaging study

    Journal of Neurology, Vol. 268, Núm. 2, pp. 582-589

2020

  1. Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease

    NeuroImage: Clinical, Vol. 28

2019

  1. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 10, pp. 2065-2076

  2. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system

    Brain, Vol. 142, Núm. 7, pp. 2023-2036

2018

  1. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

    Movement Disorders, Vol. 33, Núm. 1, pp. 117-127

  2. Patterns of grey matter loss associated with motor subscores in early Parkinson's disease

    NeuroImage: Clinical, Vol. 17, pp. 498-504

2017

  1. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease

    Scientific Reports, Vol. 7, Núm. 1

  2. Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review

    Neurological Sciences, Vol. 38, Núm. 12, pp. 2095-2101